|
|
|
| Prevention and treatment of hepatitis B recurrence after liver transplantation |
| Jian-Ping Zhu, Tong-Lin Zhang, Lei Li, Jiong Yuan, Shi-Bing Song, Dian-Rong Xiu, Kuan-Yong Hou, Tong Li and Hui Zhuang |
Beijing, China
From the Department of Surgery, Third Hospital of Peking University, Beijing 100083, China (Zhu JP, Zhang TL, Li L, Yuan J, Song SB, Xiu DR and Hou KY); Department of Microbiology, Peking University Health Science Center, Beijing 100083, China (Li T and Zhuang H)
Correspondence: Jian-Ping Zhu, MD, Department of Surgery, Third Hospital of Peking University, Beijing 100083, China (Tel: 86-10-62017691ext3217; Fax: 86-10-82084863; Email: zhujianpingwz@hahoo.com.cn) |
|
|
|
|
Abstract OBJECTIVE: To study the efficacy of liver transplantation on end-stage hepatitis B related liver diseases, and the prevention and treatment strategies of hepatitis B recurrence after the transplantation.
METHODS: The efficacy of combined treatment of lamivudine and hepatitis B immune globulin (HBIG) therapy on 24 patients who had received liver transplantation was retrospectively studied.
RESULTS: All the 24 patients with end-stage hepatitis B-related liver diseases treated with lamivudine alone or combined therapy of lamivudine and HBIG showed normal liver function and 21 of them lost hepatitis B virus (HBV) markers. However, the remaining 3 patients became HBsAg positive again soon after liver transplantation.
CONCLUSIONS: Liver transplantation is effective for patients with end-stage hepatitis B-related liver diseases. Combined treatment of lamivudine and HBIG may prevent the recurrence of hepatitis B after the operation.
|
|
|
|
|
|
|
|
|
2003, Vol. 2 
